Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). Methods: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had an estimated glomerular filtration rate (eGFR) ≥20 but <45 mL/min/1.73 m2 or an eGFR ≥45 but <90 mL/min/1.73 m2 with a urinary albumin:creatinine ratio (uACR) ≥200 mg/g. The trial design is streamlined, as extra work for collaborating sites is kept to a minimum and only essential information is collected. Results: Between 15 May 2019 and 16 April 2021, 6609 people from eight countries in Europe, North America and East Asia were randomized. The mean age at randomization was 63.8 years [standard deviation (SD) 13.9)], 2192 (33%) were female and 3570 (54%) had no prior history of DM. The mean eGFR was 37.5 mL/min/1.73 m2 (SD 14.8), including 5185 (78%) with an eGFR <45 mL/min/1.73 m2. The median uACR was 412 mg/g) (quartile 1–quartile 3 94–1190), with a uACR <300 mg/g in 3194 (48%). The causes of kidney disease included diabetic kidney disease [n = 2057 (31%)], glomerular disease [n = 1669 (25%)], hypertensive/renovascular disease [n = 1445 (22%)], other [n = 808 (12%)] and unknown causes [n = 630 (10%)]. Conclusions: EMPA-KIDNEY will evaluate the efficacy and safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression. Results are anticipated in 2022.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EMPA-KIDNEY recruited 6609 patients with chronic kidney disease including 3569 patients without diabetes”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Follow-up was planned until at least 1070 participants had experienced a first primary outcome, in order to provide 90% power at two-sided P=0.05 to detect an 18% relative reduction in risk.14”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“All trial eGFR values are estimated using the Chronic Kidney Disease Epidemiology Collaboration creatinine formula available at the start of recruitment (i.e. adjustment for race was included) [39].”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 1×
“Since then, several other large placebo-controlled cardiovascular outcome trials with other SGLT-2 inhibitors have reported analogous findings [14, 16, 17].”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 9×
“A total of 6708 participants attended a randomization visit, of which 6609 were randomized (Supplementary data, Table S3b and Figure 3). characteristics of the CREDENCE and DAPA-CKD trials [18, 23–25].”
InfluentialSelf-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 10×
“A total of 6708 participants attended a randomization visit, of which 6609 were randomized (Supplementary data, Table S3b and Figure 3). characteristics of the CREDENCE and DAPA-CKD trials [18, 23–25].”
InfluentialCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · cited 2×
“EMPA-REG OUTCOME data also raised the hypothesis—which has recently been confirmed in the EMPEROR trials [20, 21]—that empagliflozin has the potential to prevent or treat the particular types of heart disease experienced by people with CKD [8, 9, 14, 15, 35].”
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874 · cited 2×
“EMPA-REG OUTCOME data also raised the hypothesis—which has recently been confirmed in the EMPEROR trials [20, 21]—that empagliflozin has the potential to prevent or treat the particular types of heart disease experienced by people with CKD [8, 9, 14, 15, 35].”
Self-citationChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383 · cited 1×
“Establishing definitive evidence of safety and efficacy in the full range of people with CKD with and without DM has particular public health importance as, worldwide, 50–70% of people with CKD do not have DM [36, 37].”
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 4×
“Results showed empagliflozin could favourably decrease not only the risk of atherosclerotic cardiovascular disease, but also the risk of hospitalization for heart failure and the development or worsening of nephropathy [15].”
InfluentialSelf-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350 · cited 1×
“Eligible participants were then randomized using a minimization algorithm to ensure balance for important prognostic variables (see protocol for details) [40].”
Levey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841 · cited 1×
“…whether or not albuminuria is a prerequisite for renal benefits of SGLT-2 inhibitors remains an important question, as the vast majority of people with decreased eGFR do not have albuminuria [43], and CREDENCE and DAPA-CKD provide evidence of efficacy among people with albuminuria [18, 23, 25].”
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401 · cited 1×
“Chronic kidney disease (CKD) is often a progressive condition, with albuminuria representing an important risk factor for a more rapid decline in kidney function [1].”
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893 · cited 1×
“Nevertheless, results from meta-analyses of the earlier reported SGLT-2 inhibitor trials in type 2 DM encouragingly suggest renal benefits may extend to people without albuminuria [44], as do eGFR slope-based analyses in the trials among people with heart failure [20, 21, 45, 46].”
Self-citationGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Tonelli, M., Muntner, P., Lloyd, A., Manns, B. J., Klarenbach, S., Pannu, N., James, M. T., & Hemmelgarn, B. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60572-8 · Cited by 718
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B., & Schrier, R. W. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.19 · Cited by 673
Levey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620 · cited 1×
“However, when testing interventions, which can cause an acute initial decline in eGFR (such as SGLT-2 inhibitors), smaller percentage declines in eGFR may be a less specific surrogate of progression to ESKD than large percentage declines [48–51].”
Self-citationWheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556 · cited 7×
“Subgroup analyses from DAPA-CKD found that renal benefits also extend to certain types of non-diabetic causes of albuminuric CKD, including glomerulonephritis not treated with immunosuppression [25–27].”
InfluentialThe tubular hypothesis of nephron filtration and diabetic kidney disease
Vallon, V., & Thomson, S. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0256-y · Cited by 465 · cited 1×
“An acute dip in eGFR on commencing an SGLT-2 inhibitor is observed, which results from the modulation of renal tubuloglomerular feedback through decreased proximal tubular sodium resorption and subsequent glomerular afferent arteriolar vasoconstriction [15, 31].”
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338 · cited 1×
“Lowering blood pressure (BP) and low-density lipoprotein cholesterol in people with CKD decrease cardiovascular risk [11, 12], but despite such interventions, substantial residual risk remains.”
Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
Park, M., Hsu, C.-Y., Li, Y., Mishra, R. K., Keane, M., Rosas, S. E., Dries, D., Xie, D., Chen, J., He, J., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012020145 · Cited by 319 · cited 2×
“People with CKD are also at increased risk of cardiovascular disease [6, 7], a key feature of which is structural heart disease, heart failure and sudden death [8–10].”
Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050391 · Cited by 307 · cited 1×
“Nevertheless, results from meta-analyses of the earlier reported SGLT-2 inhibitor trials in type 2 DM encouragingly suggest renal benefits may extend to people without albuminuria [44], as do eGFR slope-based analyses in the trials among people with heart failure [20, 21, 45, 46].”
Zannad, F., Ferreira, J. P., Pocock, S. J., Zeller, C., Anker, S. D., Butler, J., Filippatos, G., Hauske, S. J., Brueckmann, M., Pfarr, E., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051685 · Cited by 280
Self-citationBlood Pressure Lowering Treatment Trialists' Collaboration (2013) · BMJ · doi:10.1136/bmj.f5680 · Cited by 263 · cited 1×
“Lowering blood pressure (BP) and low-density lipoprotein cholesterol in people with CKD decrease cardiovascular risk [11, 12], but despite such interventions, substantial residual risk remains.”
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237 · cited 3×
“…added to the current standard of care to slow the progression to ESKD and decrease cardiovascular risk in CKD. Inhibitors of sodium-glucose cotransporter 2 (SGLT-2) cause urinary glucose and increased sodium excretion and can decrease weight and BP as well as glycosylated haemoglobin (HbA1c) [13].”
InfluentialSelf-citationLong-term evolution of cardiomyopathy in dialysis patients
Foley, R. N., Parfrey, P. S., Kent, G. M., Harnett, J. D., Murray, D. C., & Barre, P. E. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00154.x · Cited by 226
Wheeler, D. C., Stefansson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa234 · Cited by 194 · cited 3×
“The CREDENCE and DAPA-CKD placebo-controlled trials in dedicated CKD populations were both stopped early for efficacy following recommendations from their data monitoring committees (DMCs) [18, 23, 24].”
InfluentialSelf-citationCanagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166 · cited 1×
“The rationale for testing empagliflozin in the full range of people at risk of CKD progression was based on findings from the EMPA-REG OUTCOME trial [15] and other clinical and experimental data, which showed SGLT-2 inhibitors induce glycosuria and lower BP and albuminuria [28–30].”
Baigent, C., Herrington, W. G., Coresh, J., Landray, M. J., Levin, A., Perkovic, V., Pfeffer, M. A., Rossing, P., Walsh, M., Wanner, C., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.04.019 · Cited by 146 · cited 1×
“Advantages included a semiquantitative assessment of feasibility at each prospective site, which provided early confirmation that recruitment of 6000 participants from only eight countries was possible, and decreased the likelihood of screening failures [41, 42].”
Self-citationWheeler, D. C., Jongs, N., Stefánsson, B. V., Chertow, G. M., Greene, T., Hou, F. F., Langkilde, A. M., McMurray, J. J. V., Rossing, P. R., Nowicki, M. P., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab335 · Cited by 139
International consensus definitions of clinical trial outcomes for kidney failure: 2020
Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F. E., Shahinfar, S., Tuttle, K. R., Donner, J.-A., Jha, V., Nangaku, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.07.013 · Cited by 125 · cited 1×
“Slowing of progression and avoidance of end-stage kidney disease (ESKD, also referred to as kidney failure [2]), is highly desirable due to the associated excess morbidity and mortality, adverse effects on quality of life and the substantial costs of renal replacement therapy.”
Self-citationHaynes, R., Staplin, N., Emberson, J., G. Herrington, W., Tomson, C., Agodoa, L., Tesar, V., Levin, A., Lewis, D., Reith, C., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.013 · Cited by 77 · cited 1×
“EMPA-KIDNEY employed such a definition as it aimed to recruit a large proportion of people with low levels of albuminuria and without DM who are predicted to progress more slowly than people with albuminuric diabetic CKD [47].”
Self-citationStaplin, N., Roddick, A. J., Emberson, J., Reith, C., Riding, A., Wonnacott, A., Kuverji, A., Bhandari, S., Baigent, C., Haynes, R., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101163 · Cited by 74 · cited 1×
“Trials of SGLT-2 inhibitors in patients with heart failure or CKD have also reported relative risk reductions for renal and heart failure outcomes that are similar in size in people with and without DM [18–22].”
Self-citationEnhancing clinical evidence by proactively building quality into clinical trials
Meeker-O’Connell, A., Glessner, C., Behm, M., Mulinde, J., Roach, N., Sweeney, F., Tenaerts, P., & Landray, M. (2016) · Clinical Trials · doi:10.1177/1740774516643491 · Cited by 70 · cited 1×
“These approaches were based on the principles of Quality-by-Design [38], which aims to prospectively build quality into the study design and operations rather than relying on retrospective monitoring and focusses on those factors that are critical to quality (i.e. the protection of the participants…”
Self-citationAl-Jobori, H., Daniele, G., Cersosimo, E., Triplitt, C., Mehta, R., Norton, L., DeFronzo, R. A., & Abdul-Ghani, M. (2017) · Diabetes · doi:10.2337/db17-0100 · Cited by 67
Herrington, W. G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L. H., Dendale, P., Seferovic, P., Rosano, G., Staplin, N., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2286 · Cited by 63 · cited 1×
“EMPA-REG OUTCOME data also raised the hypothesis—which has recently been confirmed in the EMPEROR trials [20, 21]—that empagliflozin has the potential to prevent or treat the particular types of heart disease experienced by people with CKD [8, 9, 14, 15, 35].”
Self-citationOgna, A., Ogna, V. F., Bochud, M., Guessous, I., Paccaud, F., Burnier, M., & Wuerzner, G. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0923-0 · Cited by 53
Suzuki, T., Agarwal, S. K., Deo, R., Sotoodehnia, N., Grams, M. E., Selvin, E., Calkins, H., Rosamond, W., Tomaselli, G., Coresh, J., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.004 · Cited by 38
Self-citationAcute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Neuen, B. L., Tighiouart, H., Heerspink, H. J. L., Vonesh, E. F., Chaudhari, J., Miao, S., Chan, T. M., Fervenza, F. C., Floege, J., Goicoechea, M., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070948 · Cited by 37 · cited 1×
“However, when testing interventions, which can cause an acute initial decline in eGFR (such as SGLT-2 inhibitors), smaller percentage declines in eGFR may be a less specific surrogate of progression to ESKD than large percentage declines [48–51].”
Self-citationChoice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
Perkovic, V., Koitka-Weber, A., Cooper, M. E., Schernthaner, G., Pfarr, E., Woerle, H. J., von Eynatten, M., & Wanner, C. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz179 · Cited by 31
Self-citationKidney disease trials for the 21st century: innovations in design and conduct
Herrington, W. G., Staplin, N., & Haynes, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0212-x · Cited by 27 · cited 1×
“Advantages included a semiquantitative assessment of feasibility at each prospective site, which provided early confirmation that recruitment of 6000 participants from only eight countries was possible, and decreased the likelihood of screening failures [41, 42].”
Self-citationDifferent eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Oshima, M., Neal, B., Toyama, T., Ohkuma, T., Li, Q., de Zeeuw, D., Heerspink, H. J. L., Mahaffey, K. W., Fulcher, G., Canovatchel, W., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019121312 · Cited by 23
Research works printed but not linked: 1
- United States Renal Data System, 2014, 2014 Annual Data Report: Atlas of End-stage Renal Disease in the United States
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
“14 The Protocol specified that a single formal interim analysis for efficacy should be conducted when 150 participants had experienced a first ESKD event.”
Self-citationBaigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Self-citationRossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Self-citation
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Staplin, N., Preiss, D., Stevens, W., Wallendszus, K., Dayanandan, R., Knott, C., Hill, M., Emberson, J., Brenner, S., Cejka, V., Cheung, A. K., Liu, Z., Li, J., Chen, P., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Goto, S., Tomita, A., Deo, R., Tuttle, K., Eilbracht, J., Hantel, S., Hopley, M., Landray, M. J., Baigent, C., Haynes, R., Baigent, C., Landray, M. J., Wanner, C., Herrington, W. G., Haynes, R., Green, J. B., Hauske, S. J., Brueckmann, M., Hopley, M., Brenner, S., Cheung, A. K., Preiss, D., Liu, Z., Li, J., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Staplin, N., Emberson, J., Hantel, S., Goto, S., Deo, R., Tuttle, K., Ng, S. Y. A., Lozano, F. J. R., Sammons, E., Zhu, D., Sandercock, P., Bilous, R., Herzog, C., Whelton, P., Wittes, J., Bennett, D., Burke, A., Brown, R., Dayanandan, R., Fletcher, L., Gosling, H., Harding, E., Haynes, R., Herrington, W. G., Judge, P., Knott, C., Lee, R., Murphy, K., Qiao, Y., Raff, R., Yu, H., Qiao, Y., Cejka, V., Fajardo-Moser, M., Lorimer, A., Lucci, D., Hepditch, A., Axler, A., Chen, P., Hao, D., Goh, C. B., Sivanandam, S., Hashimoto, A., Negoro, W., Tomita, A., & Tomoko, M.
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-03-03
- Volume
- 37
- Issue
- 7
- Pages
- 1317-1329
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC9217655
- OpenAlex
- W4213426937
- Cited by
- 110
- References
- 52
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 23 · 2023: 33 · 2022: 35
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- empagliflozin, SGLT2 inhibitors, chronic kidney disease, kidney disease progression, cardiovascular mortality, diabetic nephropathy, glomerular disease, estimated glomerular filtration rate, urinary albumin-creatinine ratio, trial recruitment, trial design, EMPA-KIDNEY trial, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Randomized Controlled Trials as Topic, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.